{"prompt": "['Protocol RS-001', 'Confidential', 'age, these young children are excluded from this study.', '4. Documentation of a diagnosis of medically intractable epilepsy as', 'defined by the failure of at least 2 appropriately dosed and tolerated', 'AEDs to eliminate all clinical seizures over a 6-month period prior', 'to epilepsy surgery', '5. Documentation of resective epilepsy surgery following appropriate', 'presurgical evaluation', '6. Documentation of continued clinical seizures that persist at least 3', 'months following resective epilepsy surgery. In order to proceed', 'with enrollment and study drug initiation, participants must have', 'had >8 seizures in the last 30 days without 2 consecutive weeks of', 'seizure freedom.', '7. Documentation that the participant is not a candidate for or refuses', 'any additional resective epilepsy surgery', '8. Participants must have adequate bone marrow function (ANC', '>1,000/mm\u00b3, platelet count of (100,000/mm\u00b3, and hemoglobin > 9', 'gm/dL) before study drug dosing.', '9. Participants must have adequate liver function (SGPT/ALT: 5', 'times ULN and bilirubin 5 times ULN) before study drug dosing.', '10. Participants must have adequate renal function before study drug', 'dosing, defined as: Creatinine clearance or radioisotope GFR', '>70mL/min/1.73 m\u00b2 or a serum creatinine based on age/gender as', 'follows:', 'Age', 'Maximum Serum', 'Creatinine (mg/dL)', 'Male', 'Female', '3 to < 6 years', '0.8', '0.8', '6 to < 10 years', '1', '1', '10 to < 13 years', '1.2', '1.2', '13 to < 16 years', '1.5', '1.4', '16 years', '1.7', '1.4', 'The threshold creatinine values in this table were derived from the Schwartz', 'formula for estimating GFR utilizing child length and stature data published', 'by the CDC.', '11. Participants must have a fasting cholesterol level <350 mg/dL and', 'triglycerides <400 mg/dL before starting study drug. In case one or', 'both of these are exceeded, the participant can only be included after', 'initiation of appropriate lipid lowering medication and', 'documentation of cholesterol <350mg/dL and triglycerides', '<400mg/dl before study drug dosing.', '12. Participants must have normal oxygen saturation before study drug', 'dosing.', '13. The effects of ABI-009 on the developing human fetus at the', 'recommended therapeutic dose are unknown. For this reason and', 'Version 2', 'Version Date: October 31, 2018', 'Page 11 of 72']['Protocol RS-001', 'Confidential', 'because ABI-009 are known to be teratogenic, participants of child-', 'bearing potential and men must agree to use adequate contraception', '(hormonal or barrier method of birth control; abstinence) prior to', 'study entry, for the duration of study participation, and for 6 months', 'after the last dose of ABI-009. Should a female participant become', 'pregnant or suspect she is pregnant while participating in this study,', 'she should inform her treating physician immediately.', 'a. Participants of child-bearing potential must not be', 'breastfeeding or pregnant as evidenced by a negative', 'pregnancy test before enrollment and before initiating study', 'drug dosing.', 'PARTICIPANT', 'Exclusion Criteria:', 'SELECTION', '1. For females of child bearing potential:', 'CRITERIA:', 'a. Positive pregnancy test at any visit or', 'Exclusion Criteria', 'b. Lactating or', 'c. Unwilling to practice a medically acceptable form of', 'contraception (acceptable forms of contraception:', 'abstinence, hormonal birth control, intrauterine device, or', 'barrier method plus a spermicidal agent), unless surgically', 'sterilized or postmenopausal during the study', '2. Participant has any other condition that, in the opinion of the Site', 'Investigator/designee, would preclude informed consent or assent,', 'make study participation unsafe, complicate interpretation of study', 'outcome data, or otherwise interfere with achieving the study', 'objectives.', '3. Participant has received immunization with attenuated live vaccines', 'within 1 week of study entry and/or is planning to receive', 'immunization with attenuated live vaccines during study period.', 'Examples of live vaccines include intranasal influenza, measles,', 'mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a', 'typhoid vaccines. Close contact with those who have received', 'attenuated live vaccines should be avoided during dosing with ABI-', '009.', '4. Participant tests positive for Hepatitis C antibodies or the Hepatitis', 'B antigen. HBsAg and HCVAb blood test must be done at screening', '(HBsAg only needs to be screened in patients who have not', 'received the full complement of Hepatitis B immunizations).', 'Alternatively, if the patient has received the complement of', 'Hepatitis B immunizations and documentation is provided, this', 'would suffice.', '5. A known history of HIV seropositivity. HIV-positive patients on', 'combination antiretroviral therapy are ineligible because of the', 'Version 2', 'Version Date: October 31, 2018', 'Page 12 of 72']\n\n###\n\n", "completion": "END"}